Clinical trial
Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
NCT03051373 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial Tract
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 1, 2017
- Completion date
- April 30, 2020
- Enrollment
- 108 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.